News

A Phase 1/2 clinical trial testing AXO-Lenti-PD (OXB102), Axovant‘s experimental gene therapy for Parkinson’s disease, has completed dosing of all four adults in a second group in its dose-escalation part of the study. Six-month data on these patients is expected by year’s end. AXO-Lenti-PD is a one-time gene therapy…

Current Parkinson’s treatments are insufficient for people with late-stage disease, inadequately controlling for many notable motor and non-motor symptoms, a study in these patients across Europe reports. The study, “The late stage of Parkinson’s — results of a large multinational study on motor and non-motor complications,” was…

A generic version of the transdermal (absorbed through the skin) Neupro patch (rotigotine), often used to ease the symptoms of Parkinson’s disease, has been developed by Vektor Pharma. …

Parkinson Voice Project has given a second grant to the Speech-Language Institute (SLI) at Salus University, enabling it to continue its SPEAK OUT! & LOUD Crowd therapy programs. Through the grant — the amount was not specified — the SLI will continue offering free group speech therapy to Parkinson’s patients…

Integrative Research Laboratories (IRLAB) is planning a Phase 2b/3 clinical trial of its investigational therapy mesdopetam (IRL790) to evaluate the therapy’s ability to reduce levodopa-induced dyskinesia (involuntary muscle movements) in people with Parkinson’s disease. IRLAB is in the process of preparing applications to relevant regulatory agencies, with…

The Open Wearables Initiative (OWEAR) is making public its software and database for wearable sensors and other related-health technologies to assist clinical research, Shimmer Research announced. “We are proud to announce the release of the OWEAR database, which includes the organization’s initial index of open source software and datasets, together…

Manus Neurodynamica, a medical technology company, has raised £750,000 in a financing round to support the rollout of NeuroMotor Pen, a digital pen with a patented sensor technology to help diagnose at early stages movement disorders like Parkinson’s disease. The funding, worth about $950,000, will also be used to…

A $3.7 million federal grant is funding a project aiming to clarify how exposure to manganese, a trace metal, affects the brain and causes cognitive problems. Findings from this research may help in better understanding Parkinson’s disease. Manganese is an essential nutrient, a mineral that is necessary in…

The U.S. Food and Drug Administration (FDA) has agreed to review Adamas Pharmaceutical’s application asking that oral Gocovri (amantadine) also be approved to treat off episodes in Parkinson’s disease patients using levodopa. An FDA decision on  the company’s supplemental new drug application (sNDA) is expected by Feb. 1, 2021.

Daily use of Nuplazid (pimavanserin) leads to strong and sustained reductions in the frequency and severity of hallucinations and delusions in people with Parkinson’s disease psychosis, according to data from a long-term extension study. These findings, “Improvement and Durability in SAPS-PD Assessment over 10…